ARTICLE | Clinical News
BDM-E: Phase I/II data
October 15, 2007 7:00 AM UTC
In a double-blind, Russian Phase I/II trial in 188 patients, BDM-E failed to significantly improve central macular thickness after 17 days compared with placebo, the primary endpoint. The compound als...